Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2022-03-09 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于变更公司营业期限、注册资本及修改《公司章程》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding changes to the company's business term, registered capital, and amendments to the Articles of Association. It details board resolutions, capital increase due to convertible bonds conversion, and specific changes to the company's charter. The document is a formal public announcement of corporate governance and capital structure changes, not a full financial report or detailed management discussion. It does not contain financial statements or earnings data, nor is it a call transcript or legal proceeding update. The content fits best under Board/Management Information (MANG) as it announces changes in company governance and capital structure approved by the board.
2022-03-09 Chinese
关于董事会和监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and composition of the company's board of directors and supervisory board. It details the nomination and election process, candidate qualifications, and includes candidate resumes. There is no financial data or report content, but rather a formal disclosure about changes in board and supervisory personnel. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-03-09 Chinese
独立董事提名人声明（何超）
Regulatory Filings
2022-03-09 Chinese
独立董事候选人声明（何超）
Regulatory Filings
2022-03-09 Chinese
第三届监事会第十六次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the third Supervisory Board of Lingkang Pharmaceutical Group Co., Ltd. It details decisions on the Supervisory Board election, changes to business term and registered capital, and importantly, a share repurchase plan including purpose, method, amount, price, and authorization. The document is relatively short (3150 characters) and is an official announcement of decisions rather than a full financial report or detailed data. It specifically discusses the company's plan to repurchase shares through centralized bidding, which fits the category of a Transaction in Own Shares (POS). There is no indication that this is a full financial report, audit, or earnings release. The document is not a report publication announcement since it contains substantive details of the resolutions. Therefore, the best classification is POS (Transaction in Own Shares).
2022-03-09 Chinese
第三届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting, including election of directors, changes to company bylaws, and a share repurchase plan. It includes voting results and references to further announcements on the stock exchange website. The content focuses on board decisions and management authorizations rather than financial results or reports. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or AGM materials. The primary focus is on board and management decisions, including changes in board composition and share repurchase authorization. Therefore, the document fits best under Board/Management Information (MANG). The document length is under 5,000 characters and contains substantive content, not just a brief announcement or certification, so it is not RPA or RNS.
2022-03-09 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.